GlassScriptPhysician profile
Michael Kevin David
NPI 1225568587
$12,557.31
in general payments reported to CMS, 2019-2025
61 companies · $2,767 in 2025
The $2,767 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $490 · 2021: $2,077 · 2022: $1,945 · 2023: $2,530 · 2024: $2,749 · 2025: $2,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,014 · Education: $31.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,014.23 |
| Education | $31.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,859.55 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,302.01 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $951.95 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $868.57 | 2020-2025 | Rexulti, Jynarque, Nuedexta |
| Lilly USA, LLC | $754.24 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $481.83 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $445.40 | 2020-2025 | Repatha, Otezla, Evenity |
| Lundbeck LLC | $420.53 | 2021-2025 | Vyepti, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $419.36 | 2020-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $299.68 | 2021-2025 | |
| Glaxosmithkline, LLC. | $291.06 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $285.72 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.87 | 2021-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $262.95 | 2020-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.11 | 2020-2025 | Jardiance |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.